Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Perianal fistulas: a new management approach using mesenchymal stem cells as a human, biological and autologous tool-a single-centre observational study.

Testa A., Passantino D., Garbarino C., Verdi A., Cozza T., Mascagni D.

Prospective Study with a reported sample of 63 on Autoimmune Research, published in Int J Colorectal Dis (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int J Colorectal Dis (2025)
Country
Germany
Reported sample size
63
Source database
PubMed
PMID
41329341
PMCID
PMC12672845
DOI
10.1007/s00384-025-05020-7

Abstract (original English)

Purpose The surgical treatment of perianal fistulas is challenging, especially in complex cases. Many surgical options may cause impairment of the anal sphincter with subsequent incontinence or may be less effective with a high number of relapses or the persistence of the pathology. New techniques, such as the use of mesenchymal stem cells, are becoming increasingly important because of their effectiveness and lower risk of complications. Methods In this single-centre prospective observational study, patients with complex perianal fistulas were treated via the infiltration of mesenchymal stem cells that had been purified using the Lipogems® system. Results This study included 63 patients with complex perianal fistulas who were treated with mesenchymal stem cells extracted from adipose tissue. Successful clinical healing was observed in 43 (68.25%) patients. Eleven (17.4%) patients presented recurrence after treatment, and 9 (14.3%) had persistent incomplete healing. Minor postoperative complications were observed in six (9.5%) patients, which were related to adipose tissue harvesting in three patients. In the majority of patients, postoperative pain was mild or not present. Conclusions Mesenchymal stem cells offer an innovative therapeutic tool for treating perianal fistulas. This study confirms their safety and efficacy in treating complex perianal fistulas. Nevertheless, more

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansRectal FistulaMesenchymal Stem Cell TransplantationMaleFemaleMiddle AgedAdultMesenchymal Stem CellsTransplantation, AutologousAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research